ClinicalTrials.Veeva

Menu
T

Tuen Mun Hospital | Department of Medicine and Geriatrics

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cisplatin
5-fluorouracil
Mycophenolate Mofetil
Tacrolimus
Pembrolizumab
Upadacitinib
Denosumab
Azacitidine
Magrolimab
Capecitabine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 54 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Crizotinib
Drug: Lorlatinib

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Carboplatin
Drug: Datopotamab Deruxtecan

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early s...

Active, not recruiting
Breast Cancer
Drug: Standard Adjuvant Endocrine Therapy
Drug: Abemaciclib

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participan...

Active, not recruiting
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Drug: NAH therapy
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the...

Active, not recruiting
Rheumatoid Arthritis
Drug: Filgotinib
Drug: Placebo to match filgotinib

The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.

Active, not recruiting
Nonmetastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Drug: Placebo
Drug: Enzalutamide

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versu...

Enrolling
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

The purpose of this study is to compare the effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants...

Active, not recruiting
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Drug: Cisplatin
Drug: Pemetrexed

Trial sponsors

T
H
Gilead Sciences logo
Pfizer logo
AbbVie logo
The University of Hong Kong (HKU) logo
Roche logo
Takeda logo
The Chinese University of Hong Kong logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems